The story on this stock has changed a bit now that Iclusig has been approved. There is significant new interest in owning the stock now that they have an approved drug, but some investors think they may be able to acquire shares at a discount if Iclusig gets off to a slow start. I think the company has (and will continue to do) practically everything possible to get the best drug for the indication into the hands of those in need. Harvey has been waiting a long time for the oppotunity to market a first class drug. We already know sales is an integral part of Harvey's skill set. :-)